Regeneron’s EYLEA HD® Achieves Key Milestone in Phase 3 QUASAR Trial for Macular Edema Due to Retinal Vein Occlusion

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (af...

December 18, 2024 | Wednesday | News
Eli Lilly’s Kisunla™ (Donanemab) Approved by China’s NMPA for Early Symptomatic Alzheimer’s Disease

Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...

December 18, 2024 | Wednesday | News
SK Biopharmaceuticals Forms Strategic Research Collaboration with ProEn Therapeutics to Advance Radiopharmaceutical Oncology Pipeline

SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous sys...

December 17, 2024 | Tuesday | News
EMA Committee Issues Positive Opinion for Long-Acting HIV Treatment Vocabria + Rekambys for Adolescents

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...

December 17, 2024 | Tuesday | News
Merck Discontinues Clinical Development of Vibostolimab and Favezelimab in Oncology Trials

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...

December 17, 2024 | Tuesday | News
Menarini, Stemline, and MEDSIR Unveil Groundbreaking ADELA Trial for Advanced ER+/HER2- Breast Cancer at SABCS 2024

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...

December 16, 2024 | Monday | News
Jaypirca® (Pirtobrutinib) Gains Approval in China for Relapsed or Refractory Mantle Cell Lymphoma

Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma ...

December 16, 2024 | Monday | News
Eli Lilly's Omvoh® (Mirikizumab) Receives Positive CHMP Opinion for Crohn’s Disease in the EU

Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

December 16, 2024 | Monday | News
Merck’s WELIREG® Receives Positive CHMP Opinion for VHL Disease-Associated Tumors and Advanced RCC in the EU

Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...

December 16, 2024 | Monday | News
A2A Pharmaceuticals Advances Phase 1 Clinical Trial of TACC3 Inhibitor A0-252 in Ovarian, TNBC, and Endometrial Cancers

A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...

December 13, 2024 | Friday | News
Imlunestrant Shows Significant PFS Improvement in Phase 3 EMBER-3 Trial for ER+ HER2- Advanced Breast Cancer

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...

December 13, 2024 | Friday | News
Shaping Biopharma Purification: Phenomenex’s Vision for 2025

Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...

December 12, 2024 | Thursday | Opinion
Redefining Precision Medicine: Demaris Mills on IDT’s Role in Precision Medicine and Gene Synthesis for 2025

In a thought-provoking Q&A with BioPharma BoardRoom, Demaris Mills, President of Integrated DNA Technologies (IDT), discusses the transformative advanc...

December 12, 2024 | Thursday | Interaction
Shaping the Future of Gene Therapy: Kerstin Pohl on Analytical Innovations for 2025

In a detailed interview with BioPharma BoardRoom, Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into t...

December 12, 2024 | Thursday | Interaction

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close